Protagenic Therapeutics, Inc. (PTIX)
| Market Cap | 1.48M -82.3% |
| Revenue (ttm) | n/a |
| Net Income | 5.46M |
| EPS | 2.94 |
| Shares Out | 1.81M |
| PE Ratio | 0.28 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,303 |
| Open | 0.81638 |
| Previous Close | 0.8600 |
| Day's Range | 0.81638 - 0.81638 |
| 52-Week Range | 0.1282 - 4.4300 |
| Beta | 0.38 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 19, 2026 |
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. The company was founded in 2004 and is based in New York, New York. [Read more]
Financial Performance
Financial StatementsNews
Protagenic receives FDA pre-IND feedback supporting IND for PT00114
Protagenic Therapeutics (PTIX) announced that it has received written responses from the U.S. Food and Drug Administration, FDA, to its Type B pre-Investigational New Drug, pre-IND, meeting request fo...
Protagenic Therapeutics Receives FDA Pre-IND Feedback Supporting New IND for PT00114 in Generalized Anxiety Disorder
FDA raises no objection to the Company's planned Phase 1 program design, dose-escalation approach, or CMC and nonclinical packages; IND submission remains on track for the fourth quarter of 2026 NEW Y...
Protagenic Therapeutics announces publication of PT00114 preclinical data
Protagenic Therapeutics (PTIX) announced the publication of new preclinical data for its lead candidate, PT00114, in the peer-reviewed journal Behavioural Pharmacology. In a well-established rodent mo...
Protagenic Therapeutics' Lead Candidate PT00114 Attenuated Chronic Stress Responses in a Well-Established Rodent Model
As published in Behavioural Pharmacology, two days of PT00114 treatment reduced corticosterone levels and attenuated anxiety-like behavior in chronically stressed rats; a known CRF₁ receptor antagonis...
Protagenic announces two engagements to support advancement of PT00114
Protagenic Therapeutics (PTIX) announced two strategic engagements to support the advancement of its lead candidate, PT00114. The Company has engaged Floyd Regulatory Strategic Consulting, led by regu...
Protagenic Therapeutics Engages Floyd Regulatory Strategic Consulting as Regulatory Affairs Advisor and Danforth Health as Strategic Operations Partner
NEW YORK, NY / ACCESS Newswire / May 19, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company developing novel peptide-based therapies for stress-related neuro...
Protagenic Therapeutics appoints Nichols Jr. as President
Protagenic Therapeutics (PTIX) announced the appointment of Bill Nichols Jr. as President. At Protagenic, Nichols will drive integrated clinical development, corporate strategy, and enterprise plannin...
Protagenic Therapeutics Appoints Industry Veteran Bill Nichols Jr. as President to Accelerate Advancement of First-in-Class TCAP Pathway Therapy PT00114
NEW YORK, NY / ACCESS Newswire / April 23, 2026 / Protagenic Therapeutics, Inc. (OTCQB:PTIX), a clinical-stage biopharmaceutical company pioneering first-in-class neuropeptide therapies for stress-rel...
Protagenic Therapeutics completes Phytanix separation
Protagenic Therapeutics (PTIX) announced the closing of a settlement and separation related to its prior Phytanix Bio acquisition. The transaction simplifies Protagenic’s capital structure, materially...
Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114
Returned and cancelled merger shares, removal of more than $6.3 million of liabilities and over $1 million of annualized cost savings position Protagenic as a leaner company centered on PT00114 NEW YO...
Protagenic Therapeutics upgrades from OTC Pink to OTCQB Venture Market
Protagenic Therapeutics (PTIX) announced that its common stock has been upgraded from OTC Pink to the OTCQB and has commenced trading on OTCQB under the symbol “PTIX.” Published first on…
Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market
Move strengthens market visibility, supports liquidity and real-time quote access as PT00114 advances toward Phase 2 in 2026 NEW YORK CITY, NY / ACCESS Newswire / March 10, 2026 / Protagenic Therapeut...
Protagenic reports results from Phase 1 multiple-dose study of PT00114
Protagenic Therapeutics (PTIX) reported topline safety results from its Phase 1 Multiple Dose study of PT00114. PT00114 is a synthetic analogue of a naturally occurring brain peptide thought to be…
Results from Phase 1 Multiple-Dose Study of PT00114
Findings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protage...
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice
NEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") today announced that it has received a notification letter from the Nasdaq Listing Qual...
Protagenic Therapeutics completes enrollment, dosing in Phase 1 MAD study
Protagenic Therapeutics (PTIX) announced the completion of enrollment and dosing in its Multiple Ascending Dose Phase 1 study evaluating its lead compound, known as PT00114. The study, conducted in he...
Protagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD Study
NEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. (NASDAQ:PTIX), a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and ...
Protagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq Compliance
Delay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX), a biopharmaceutical company developing nove...
Protagenic advances PT00114 into multiple-dose Phase 1 trial
Protagenic Therapeutics (PTIX) announced completion of first dose injection for all study subjects in the multiple-dose portion of its ongoing Phase I clinical trial of PT00114. The company expects to...
Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders
Dosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX), a biopharmaceuti...
Protagenic Therapeutics granted new patent in Japan for modified stilbenoid
Protagenic Therapeutics (PTIX) announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of…
Protagenic Therapeutics receives $3.1M from warrant activity
Protagenic Therapeutics (PTIX) announced that warrant exchanges and exercises over the last four trading days have generated $3.1M in cash. The proceeds will fund working-capital needs and advance the...
Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have ge...
Protagenic Therapeutics, Phytanix Bio to combine in all-stock transaction
Protagenic Therapeutics (PTIX) and Phytanix Bio have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. The combined entity...
Protagenic Therapeutics, Phytanix Bio enter business combination agreement
Protagenic Therapeutics (PTIX) and Phytanix Bio entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction. The combined entity, to ...